

NOTICE: VA Offer of Exclusive Patent License to Griffon Pharmaceuticals Inc.

BY THE: Department of Veterans Affairs, Office of Research and Development (VA)

ON: Jan 25, 2021

SUMMARY: Notice is hereby given that the Department of Veterans Affairs (VA), Office of Research and Development, Technology Transfer Program, intends to grant to Griffon Pharmaceuticals Inc., 7140 Alfred Nobel, Montreal, QC H4S 2C1, Canada an exclusive license to U.S. Patent Application No. 16/611,147 and PCT/US2018/031261, associated with VA Invention Disclosure number 2016-145 titled, "Methods and Composition for Treating Liver Disease".

TECH NAME: "Methods and Composition for Treating Liver Disease"

ACTION: Intent

DATES: Comments must be received on or before February 10, 2021.

ADDRESS: Send comments to Mr. Stefan Susta, Technology Transfer Specialist, Office of Research and Development (14RDTT), Department of Veterans Affairs, 810 Vermont Avenue, NW., Washington, DC 20420, (937) 409-7993 (this is not a toll-free number), Email: stefan.susta@va.gov

FOR FURTHER INFORMATION CONTACT: Send comments to Mr. Stefan Susta, Technology Transfer Specialist, Office of Research and Development (14RDTT), Department of Veterans Affairs, 810 Vermont Avenue, NW., Washington, DC 20420, (937) 409-7993 (this is not a toll-free number), Email: stefan.susta@va.gov

SUPPLEMENTARY INFORMATION: The Federal Government's patent rights in this invention are assigned to the US Government as represented by the Department of Veterans Affairs. It is in the public interest to license this invention as Griffon Pharmaceuticals, Inc. has submitted a complete and sufficient application for a license. The prospective exclusive license will be royalty-bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. The prospective exclusive license may be granted unless, within 15 days from the date of this published Notice, the Department of Veterans Affairs Office of Research and Development, Technology Transfer Program receives written evidence and argument which establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7.